ECSP21050201A - Inhibidores de imidazo[1,2-b]piridazina il-17a - Google Patents
Inhibidores de imidazo[1,2-b]piridazina il-17aInfo
- Publication number
- ECSP21050201A ECSP21050201A ECSENADI202150201A ECDI202150201A ECSP21050201A EC SP21050201 A ECSP21050201 A EC SP21050201A EC SENADI202150201 A ECSENADI202150201 A EC SENADI202150201A EC DI202150201 A ECDI202150201 A EC DI202150201A EC SP21050201 A ECSP21050201 A EC SP21050201A
- Authority
- EC
- Ecuador
- Prior art keywords
- inhibitors
- imidazine
- pyridazine
- formula
- imidazopyridazinyl
- Prior art date
Links
- 102000013691 Interleukin-17 Human genes 0.000 title abstract 2
- 108050003558 Interleukin-17 Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 title 1
- KGHLHKZDSODELI-UHFFFAOYSA-N 3-cyclohexyl-4,4-difluoro-1-(5H-imidazo[4,5-c]pyridazin-3-yl)imidazolidin-2-one Chemical class FC1(N(C(N(C1)C1=NNC=2C(=C1)N=CN=2)=O)C1CCCCC1)F KGHLHKZDSODELI-UHFFFAOYSA-N 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
Abstract
La invención proporciona ciertos compuestos de difluorociclohexil-imidazopiridazinil-imidazolidinona de Fórmula II como inhibidores de IL-17A, composiciones farmacéuticas de estos, y métodos para usar un compuesto de la Fórmula II para tratar ciertos síntomas de psoriasis, artritis reumatoide o esclerosis múltiple.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962789247P | 2019-01-07 | 2019-01-07 | |
| US201962842770P | 2019-05-03 | 2019-05-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP21050201A true ECSP21050201A (es) | 2021-08-31 |
Family
ID=69423406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202150201A ECSP21050201A (es) | 2019-01-07 | 2021-07-07 | Inhibidores de imidazo[1,2-b]piridazina il-17a |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US12252491B2 (es) |
| EP (1) | EP3908585B1 (es) |
| JP (1) | JP7291226B2 (es) |
| KR (1) | KR102600451B1 (es) |
| CN (1) | CN113286795B (es) |
| AU (1) | AU2020207196B2 (es) |
| BR (1) | BR112021011095B1 (es) |
| CA (1) | CA3125788C (es) |
| CL (1) | CL2021001720A1 (es) |
| CO (1) | CO2021008776A2 (es) |
| CR (1) | CR20210357A (es) |
| DO (1) | DOP2021000132A (es) |
| EC (1) | ECSP21050201A (es) |
| ES (1) | ES2977743T3 (es) |
| IL (1) | IL284228B2 (es) |
| JO (1) | JOP20210179A1 (es) |
| MA (1) | MA54696A (es) |
| MX (1) | MX2021008176A (es) |
| NZ (1) | NZ777806A (es) |
| PE (1) | PE20212304A1 (es) |
| PH (1) | PH12021551632A1 (es) |
| SA (1) | SA521422452B1 (es) |
| SG (1) | SG11202105776WA (es) |
| TW (2) | TWI752400B (es) |
| WO (1) | WO2020146194A1 (es) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA129589C2 (uk) | 2018-12-19 | 2025-06-11 | Лео Фарма А/С | Аніліди амінокислот як низькомолекулярні модулятори il-17 |
| GB201909190D0 (en) * | 2019-06-26 | 2019-08-07 | Ucb Biopharma Sprl | Therapeutic agents |
| PE20230469A1 (es) | 2020-04-30 | 2023-03-14 | Janssen Pharmaceutica Nv | Imidazopiridazinas como moduladores de il-17 |
| EP4168114A1 (en) | 2020-06-12 | 2023-04-26 | LEO Pharma A/S | Small molecule modulators of il-17 |
| WO2021255086A1 (en) | 2020-06-18 | 2021-12-23 | Leo Pharma A/S | Small molecule modulators of il-17 |
| US20230227435A1 (en) | 2020-06-18 | 2023-07-20 | Leo Pharma A/S | Small molecule modulators of il-17 |
| WO2021255085A1 (en) | 2020-06-18 | 2021-12-23 | Leo Pharma A/S | Small molecule modulators of il-17 |
| EP3943495A1 (en) | 2020-07-24 | 2022-01-26 | Leo Pharma A/S | Small molecule modulators of il-17 |
| CN113999234B (zh) * | 2020-07-28 | 2023-03-07 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| WO2022096411A1 (en) | 2020-11-09 | 2022-05-12 | UCB Biopharma SRL | Dicyclopropylmethyl derivatives as il-17 modulators |
| CA3199816A1 (en) | 2020-11-09 | 2022-05-12 | UCB Biopharma SRL | Dicyclopropylmethyl derivatives as il-17 modulators |
| JP7827725B2 (ja) * | 2020-12-14 | 2026-03-10 | ユーシービー バイオファルマ エスアールエル | Ｉｌ－１７モジュレータとしてのイミダゾピリダジン誘導体 |
| AR126255A1 (es) | 2021-07-01 | 2023-10-04 | UCB Biopharma SRL | Derivados de imidazotriazina como moduladores de il-17 |
| WO2023025783A1 (en) | 2021-08-23 | 2023-03-02 | Leo Pharma A/S | Small molecule modulators of il-17 |
| CA3233625A1 (en) * | 2021-09-27 | 2023-03-30 | Janssen Pharmaceutica Nv | Imidazopyridazine il-17 inhibitor compounds |
| US12173007B2 (en) * | 2021-09-27 | 2024-12-24 | Janssen Pharmaceutica Nv | Imidazopyridazine IL-17 inhibitor compounds |
| WO2023078319A1 (zh) * | 2021-11-04 | 2023-05-11 | 海思科医药集团股份有限公司 | 一种可抑制il-17a的杂环化合物及其用途 |
| WO2023111181A1 (en) | 2021-12-16 | 2023-06-22 | Leo Pharma A/S | Small molecule modulators of il-17 |
| EP4486737A1 (en) | 2022-03-04 | 2025-01-08 | LEO Pharma A/S | Small molecule modulators of il-17 |
| CN114736104B (zh) * | 2022-04-20 | 2024-04-19 | 上海恩氟佳科技有限公司 | 一种二氟乙醛缩半乙醇的合成方法 |
| EP4525987A1 (en) * | 2022-05-19 | 2025-03-26 | Dice Alpha, Inc. | Lactam substituted imidazopyridazine il-17a modulators and uses thereof |
| GB202210731D0 (en) | 2022-07-22 | 2022-09-07 | UCB Biopharma SRL | Therapeutic agents |
| WO2024115662A1 (en) | 2022-12-02 | 2024-06-06 | Leo Pharma A/S | Small molecule modulators of il-17 |
| WO2024138286A1 (en) * | 2022-12-26 | 2024-07-04 | Usynova Pharmaceuticals, Ltd. | Il-17a modulators |
| AU2024213283A1 (en) * | 2023-01-30 | 2025-08-14 | Dice Alpha, Inc. | Benzimidazole and aza-benzimidazole based il-17a modulators and uses thereof |
| CR20250339A (es) * | 2023-02-13 | 2025-09-26 | Dice Alpha Inc | Moduladores de il-17a de imidazotriazina y usos de estos |
| EP4688156A1 (en) * | 2023-03-28 | 2026-02-11 | Janssen Pharmaceutica NV | Lactam-containing imidazopyridazine il-17 inhibitor compounds |
| EP4695254A1 (en) * | 2023-04-11 | 2026-02-18 | Dice Alpha, Inc. | Substituted 6-imidazopyridazine il-17a modulators and uses thereof |
| WO2025133234A1 (en) | 2023-12-22 | 2025-06-26 | Draupnir Bio Aps | Sortilin binders and bifunctional compounds thereof |
| WO2025175249A1 (en) | 2024-02-14 | 2025-08-21 | Olema Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
| WO2025247285A1 (zh) * | 2024-05-28 | 2025-12-04 | 西藏海思科制药有限公司 | 一种可抑制il-17a的杂环化合物制备及其用途 |
| WO2026039171A1 (en) | 2024-08-12 | 2026-02-19 | Dice Alpha, Inc. | Il-17a inhibitors |
| WO2026039170A1 (en) | 2024-08-12 | 2026-02-19 | Dice Alpha, Inc. | Il-17a inhibitors |
| WO2026039172A1 (en) | 2024-08-12 | 2026-02-19 | Dice Alpha, Inc. | Il-17a inhibitors |
| WO2026039168A1 (en) | 2024-08-12 | 2026-02-19 | Dice Alpha, Inc. | Il-17a inhibitors |
| WO2026039167A1 (en) | 2024-08-12 | 2026-02-19 | Dice Alpha, Inc. | Il-17a inhibitors |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9702213D0 (en) * | 1996-02-24 | 1997-03-26 | Zeneca Ltd | Chemical compounds |
| EP1910369A1 (en) * | 2005-07-29 | 2008-04-16 | Astellas Pharma Inc. | Fused heterocycles as lck inhibitors |
| WO2007104696A1 (en) * | 2006-03-15 | 2007-09-20 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Antimalarial agents having polyaromatic structure |
| CA2669399A1 (en) * | 2006-11-13 | 2008-05-29 | Eli Lilly & Co. | Thienopyrimidinones for treatment of inflammatory disorders and cancers |
| WO2013116682A1 (en) | 2012-02-02 | 2013-08-08 | Ensemble Therapeutics Corporation | Macrocyclic compounds for modulating il-17 |
| ES2666353T3 (es) * | 2012-09-06 | 2018-05-04 | Bristol-Myers Squibb Company | Inhibidores de JAK3 de imidazopiridazina y su uso para el tratamiento de enfermedades inflamatorias y autoinmunitarias |
| WO2014066726A2 (en) | 2012-10-26 | 2014-05-01 | Ensemble Therapeutics Corporation | Compounds for modulating il-17 |
| UA112028C2 (uk) * | 2012-12-14 | 2016-07-11 | Пфайзер Лімітед | Похідні імідазопіридазину як модулятори гамка-рецептора |
| HK1212699A1 (zh) | 2013-02-20 | 2016-06-17 | 拜耳医药股份公司 | 作为mknk1抑制剂的取代的咪唑并[1，2-b]哒嗪类化合物 |
| ES2702126T3 (es) * | 2013-12-10 | 2019-02-27 | Bristol Myers Squibb Co | Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa |
| WO2016037171A1 (en) | 2014-09-05 | 2016-03-10 | The Cleveland Clinic Foundation | Flavonoid il-17a inhibitors |
| CA2998681C (en) | 2015-09-23 | 2024-02-06 | Reata Pharmaceuticals, Inc. | C4-modified oleanolic acid derivatives for inhibition of il-17 and other uses |
| ES2828733T3 (es) * | 2015-11-18 | 2021-05-27 | Bristol Myers Squibb Co | Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa |
| GB201709456D0 (en) | 2017-06-14 | 2017-07-26 | Ucb Biopharma Sprl | Therapeutic agents |
| JP7271557B2 (ja) | 2018-01-15 | 2023-05-11 | ユーシービー バイオファルマ エスアールエル | Ｉｌ－１７モジュレータとしての縮合イミダゾール誘導体 |
| CN110511213B (zh) | 2018-05-22 | 2021-10-19 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| UA129589C2 (uk) | 2018-12-19 | 2025-06-11 | Лео Фарма А/С | Аніліди амінокислот як низькомолекулярні модулятори il-17 |
| EP3921038A1 (en) | 2019-02-06 | 2021-12-15 | Dice Alpha, Inc. | Il-17a modulators and uses thereof |
-
2020
- 2020-01-02 TW TW109100073A patent/TWI752400B/zh not_active IP Right Cessation
- 2020-01-02 TW TW111100669A patent/TW202214648A/zh unknown
- 2020-01-03 JP JP2021539549A patent/JP7291226B2/ja active Active
- 2020-01-03 KR KR1020217020765A patent/KR102600451B1/ko active Active
- 2020-01-03 IL IL284228A patent/IL284228B2/en unknown
- 2020-01-03 EP EP20703322.6A patent/EP3908585B1/en active Active
- 2020-01-03 CN CN202080008309.9A patent/CN113286795B/zh active Active
- 2020-01-03 MX MX2021008176A patent/MX2021008176A/es unknown
- 2020-01-03 SG SG11202105776WA patent/SG11202105776WA/en unknown
- 2020-01-03 BR BR112021011095-0A patent/BR112021011095B1/pt active IP Right Grant
- 2020-01-03 MA MA054696A patent/MA54696A/fr unknown
- 2020-01-03 US US17/419,997 patent/US12252491B2/en active Active
- 2020-01-03 PE PE2021001117A patent/PE20212304A1/es unknown
- 2020-01-03 CR CR20210357A patent/CR20210357A/es unknown
- 2020-01-03 AU AU2020207196A patent/AU2020207196B2/en active Active
- 2020-01-03 WO PCT/US2020/012115 patent/WO2020146194A1/en not_active Ceased
- 2020-01-03 CA CA3125788A patent/CA3125788C/en active Active
- 2020-01-03 PH PH1/2021/551632A patent/PH12021551632A1/en unknown
- 2020-01-03 NZ NZ777806A patent/NZ777806A/en unknown
- 2020-01-03 ES ES20703322T patent/ES2977743T3/es active Active
-
2021
- 2021-06-22 DO DO2021000132A patent/DOP2021000132A/es unknown
- 2021-06-25 CL CL2021001720A patent/CL2021001720A1/es unknown
- 2021-07-01 SA SA521422452A patent/SA521422452B1/ar unknown
- 2021-07-01 CO CONC2021/0008776A patent/CO2021008776A2/es unknown
- 2021-07-07 JO JOP/2021/0179A patent/JOP20210179A1/ar unknown
- 2021-07-07 EC ECSENADI202150201A patent/ECSP21050201A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP21050201A (es) | Inhibidores de imidazo[1,2-b]piridazina il-17a | |
| ECSP22087539A (es) | Inhibidores de kras tricíclicos fusionados | |
| ECSP22029777A (es) | Heterociclos bic?clicos como inhibidores de fgfr | |
| CL2021002882A1 (es) | Inhibidores de fgfr y métodos de uso de los mismos | |
| EA201992584A1 (ru) | Новые ингибиторы map4k1 | |
| PH12019502264A1 (en) | Fused imidazo-piperidine jak inhibitors compound | |
| MX2022007171A (es) | Compuestos cíclicos y métodos de uso de estos. | |
| EA201290305A1 (ru) | Производные трициклического пиразоламина | |
| UA113156C2 (xx) | Циклобутилзаміщені похідні піролопіридину й піролопіримідину як інгібітори jak | |
| ES2192192T3 (es) | Dieteres de catecol como inhibidores selectivos de pde iv. | |
| CL2020002275A1 (es) | Compuestos diólicos de aminopirazina como inhibidores de pi3k-y. | |
| EA201890072A1 (ru) | Новые соединения в качестве модуляторов ror-гамма | |
| MX2022002711A (es) | Nuevos inhibidores heterociclicos de monoacilglicerol lipasa (magl). | |
| NI202100020A (es) | Inhibidores de pde4 que contienen boro | |
| PA8601001A1 (es) | Fenacilo 2-hidroxi-3-diaminoalcanos | |
| BR112022005627A2 (pt) | Composto de fórmula estrutural i ou um sal do mesmo, composição farmacêutica e uso de um composto | |
| MX383520B (es) | Nuevos compuestos de tipo tetrahidropirimidodiazepina y dihidropiridodiazepina para tratar el dolor y afecciones relacionadas con el dolor | |
| BR112022013488A2 (pt) | Pirazolo-pirimidinas substituídas e seu uso | |
| MX2022004565A (es) | Tienopirimidonas como inhibidores de trpa1. | |
| CL2024002824A1 (es) | Inhibidores de tyk2 y usos de los mismos | |
| BR112016023299A8 (pt) | composto tricíclico e inibidor de jak, agente preventivo, terapêutico ou de melhoria para doenças contra as quais inibição de jak é eficaz e para artrite reumatoide, medicamento e utilização desses compostos | |
| JOP20240266A1 (ar) | مركبات تريازولو ثلاثية الحلقة كمثبطات dgk | |
| MX2022004564A (es) | Tienopirimidonas como inhibidores de trpa1. | |
| MX2023009059A (es) | Antagonistas de gpr84 y usos de estos. | |
| EA202191464A1 (ru) | ИМИДАЗО[1,2-b]ПИРИДАЗИНОВЫЕ ИНГИБИТОРЫ IL-17A |